Clinical Cancer Research CR Surrogrates Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reddy, P. S.
Right arrow Articles by Yu, D.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reddy, P. S.
Right arrow Articles by Yu, D.-C.
Related Collections
Right arrowCommentary
Clinical Cancer Research Vol. 12, 2869-2878, May 1, 2006
© 2006 American Association for Cancer Research


Cancer Therapy: Preclinical

Enhanced Gene Transfer and Oncolysis of Head and Neck Cancer and Melanoma Cells by Fiber Chimeric Oncolytic Adenoviruses

P. Seshidhar Reddy, Shanthi Ganesh and De-Chao Yu

Author's Affiliation: Cell Genesys, Inc., South San Francisco, California

Requests for reprints: Shanthi Ganesh, Oncolytic Virus Research, Cell Genesys, Inc., 500 Forbes Boulevard, South San Francisco, CA 94080. Phone: 650-266-2925; E-mail: shanthi.ganesh{at}cellgenesys.com.

Purpose: The purpose of this study was to evaluate a fiber knob replacement strategy to improve infectivity and efficacy of Ad5 fiber chimeric oncolytic viruses for treatment of melanoma and head and neck cancers (HNC).

Experimental Design: Adenoviral receptors and transduction levels were used to determine the level of infectivity of fiber-modified, green fluorescent protein–expressing, replication-deficient viruses in a panel of melanoma and HNC cell lines in vitro. Virus yield and cytotoxicity assays were used to determine the tumor specificity and virus replication-mediated cytotoxicity of the fiber-modified oncolytic viruses in the same panel of melanoma and HNC in vitro. Xenograft tumor models were used to assess the antitumor activity of those fiber-modified chimeric viruses compared with the parental virus.

Results: Marker gene expression following gene transfer of the fiber chimeric vectors in melanoma and HNC cell lines was ~10-fold higher than that obtained with parental Ad5 vector. The fiber chimeric oncolytic variants mediated killing of melanoma and HNC cells that was 2- to 576-fold better than with the parental virus. In addition, fiber chimeric variants produced 2- to 7-fold more progeny virus in tumor cells than the parental virus. Moreover, a high multiplicity of infection was needed for the fiber chimeric viruses to produce cytotoxicity in normal cells. A significantly stronger antitumor response and survival advantage were shown in the tested melanoma and HNC xenograft models following i.t. injections.

Conclusions: In vitro and in vivo studies showed the improved transduction, replication, cytotoxicity, antitumor efficacy, and survival advantage in melanoma and HNC tumor models, suggesting a potential use of these oncolytic agents for the treatment of melanoma and HNCs.


Commentary

Advanced Generation Adenoviral Virotherapy Agents Embody Enhanced Potency Based upon CAR-Independent Tropism
J. Michael Mathis, Phoebe L. Stewart, Zheng B. Zhu, and David T. Curiel
Clin. Cancer Res. 2006 12: 2651-2656. [Full Text] [PDF]



This article has been cited by other articles:


Home page
J. Virol.Home page
M. Robinson, B. Li, Y. Ge, D. Ko, S. Yendluri, T. Harding, M. VanRoey, K. R. Spindler, and K. Jooss
Novel Immunocompetent Murine Tumor Model for Evaluation of Conditionally Replication-Competent (Oncolytic) Murine Adenoviral Vectors
J. Virol., April 15, 2009; 83(8): 3450 - 3462.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Peled, A. Shaish, A. Katav, S. Greenberger, I. Barshack, R. Tal, L. Bangio, E. Breitbart, and D. Harats
Systemic Administration of a Conditionally Replicating Adenovirus, Targeted to Angiogenesis, Reduced Lung Metastases Burden in Cotton Rats
Clin. Cancer Res., March 1, 2009; 15(5): 1664 - 1673.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Ganesh, M. Gonzalez-Edick, D. Gibbons, M. Van Roey, and K. Jooss
Intratumoral Coadministration of Hyaluronidase Enzyme and Oncolytic Adenoviruses Enhances Virus Potency in Metastatic Tumor Models
Clin. Cancer Res., June 15, 2008; 14(12): 3933 - 3941.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Ganesh, M. Gonzalez Edick, N. Idamakanti, M. Abramova, M. VanRoey, M. Robinson, C.-O. Yun, and K. Jooss
Relaxin-Expressing, Fiber Chimeric Oncolytic Adenovirus Prolongs Survival of Tumor-Bearing Mice
Cancer Res., May 1, 2007; 67(9): 4399 - 4407.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. M. Mathis, P. L. Stewart, Z. B. Zhu, and D. T. Curiel
Advanced Generation Adenoviral Virotherapy Agents Embody Enhanced Potency Based upon CAR-Independent Tropism.
Clin. Cancer Res., May 1, 2006; 12(9): 2651 - 2656.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.